Targeted Chemotherapy for Ovarian Cancer with Homologous Recombination Deficiency of late relapse Randomized clinical trial comparing liposomal doxorubicin plus carboplatin vs. paclitaxel plus carboplatin for recurrent, platinum- sensitive epithelial ovarian cancer with dysfunctional homologous recombination pathway Ting-Chang Chang, MD, MPH Professor and Chairman, Chang Gung Memorial Hospitals, North Taiwan President, Taiwan Precision Medicine Society
23
Embed
Targeted chemotherapy for BRCA-Mutated Ovarian Cancer Oct AGOG slides OV proposal... · CALYPSO ROC relapsing > 6 months after first- or second-line therapy Pegylated liposomal doxorubicin
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Targeted Chemotherapy for Ovarian Cancer with Homologous Recombination
Deficiency of late relapse
Randomized clinical trial comparing liposomal doxorubicin plus carboplatin vs. paclitaxel plus carboplatin for recurrent, platinum-sensitive epithelial ovarian cancer with dysfunctional homologous
recombination pathway
Ting-Chang Chang, MD, MPHProfessor and Chairman, Chang Gung Memorial Hospitals, North TaiwanPresident, Taiwan Precision Medicine Society
Sensitivity and improved survival are hallmarks of BRCA-mutated and BRCA-ness EOC
• Attributed to the homologous recombination deficiency in the absence of BRCA1/BRCA2/RAD51 function• Impaired ability to repair DNA double strain breaks
• Increased sensitivity to • Cisplatin/carboplatin
• doxorubicin
• trabectedin
• mitomycin C
• etoposide
• topotecan
• irinotecan
CALYPSOROC relapsing > 6 months after first- or second-line therapyPegylated liposomal doxorubicin (30 mg/m2) and carboplatin (AUC 5) at 4-week intervals vs. paclitaxel (175 mg/m2) and carboplatin (AUC 5) at 3-week intervals
Eric Pujade-Lauraine et al. JCO 2010;28:3323-3329 British Journal of Cancer (2012) 107, 588–591
CALYPSO
MITO-2Chemotherapy-naïve, IC - IV ovarian cancer randomly assigned to carboplatin AUC 5 + paclitaxel 175 mg/m2 or to carboplatin AUC 5 + PLD 30 mg/m2, every 3 weeks for 6 cycles.
Study regimens and compliance in CALYPSO and MITO-2Regimen Compliance
MITO-2PLD 30 mg/m2 + Carbo AUC 5, every 3 wks
81% completed 6 cycles vs. 86% of control
34.5% of cycles delayed vs. 11.5% in control
CALYPSOPLD 30 mg/m2 + Carbo, AUC 5 every 4 wks 85% completed 6 cycles vs.
77% of control
21 wks of treatment duration vs. 16 wks in control
Control (both)Pacliaxel 175mg/m2 + Carbo AUC 5, every 3 wks
Hypothetical Distributions of BRCA mutation or BRCAnessin primary and in platinum-sensitive recurrent Epithelial Ovarian Cancer
Primary Platinum Sensitive Recurrent
Clinical trial proposal
• A Randomized, Open-label, Multicenter, Phase III Study to Compare the Efficacy of Liposomal Doxorubicin plus Carboplatin versus Paclitaxel plus Carboplatin in Patients with BRCA-mutated Epithelial Ovarian Cancer of late relapse
• A Randomized, Open-label, Multicenter Study to Compare the Efficacy of Liposomal Doxorubicin plus Carboplatin versus Paclitaxel plus Carboplatin in Patients with previously untreated BRCA-mutated Epithelial Ovarian Cancer
platinum-sensitive recurrent epithelial ovarian cancer